Logo

Rocket Pharmaceuticals, Inc.

RCKT

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; le… read more

Healthcare

Biotechnology

11 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$3.34

Price

-1.77%

-$0.06

Market Cap

$364.706m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financial Reports

Key metrics over the past few years and other important metrics. Amounts in USD.

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$0.00

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$209.383m

+6.2%

1y CAGR

+4.9%

3y CAGR

+1.0%

5y CAGR
EPS

-$1.87

+7.0%

1y CAGR

+13.3%

3y CAGR

+12.6%

5y CAGR
Book Value

$238.039m

$285.407m

Assets

$47.368m

Liabilities

$24.764m

Debt
Debt to Assets

8.7%

-0.1x

Debt to EBITDA
Free Cash Flow

-$179.795m

+5.6%

1y CAGR

+5.1%

3y CAGR

+0.5%

5y CAGR
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases